Robert Garnick joins Peregrine

This article was originally published in SRA

22 Oct 2009
News

Executive Summary

Peregrine Pharmaceuticals in the US has appointed Robert Garnick head of regulatory affairs. Dr Garnick will be responsible for overseeing Peregrine's interactions with the US Food and Drug Administration and global regulatory agencies; he will also lead the development of regulatory strategies for advancing the company's monoclonal antibody-based treatments for cancer and infectious diseases.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS114760

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS114760

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Robert Garnick joins Peregrine

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert